Betting on Beads
Executive Summary
Four year old Luminex appears to be in the right place at the right time, but it faces increasing competition in a confusing field. The company has, in only a few short years, launched two generations of products, completed a successful IPO, and captured the attention of life scientists, who are scrambling for inexpensive, fast tools that can do genetic and proteomic analysis. Luminex has a simple-to-use multiplexing platform, which is flexible and inexpensive enough to be easily adapted to fields as diverse as genomics and clinical diagnostics.